TTNP - タイタン・ファ―マシュ―ティカルズ （Titan Pharmaceuticals Inc.） タイタン・ファ―マシュ―ティカルズTTNPのチャート
TTNPの企業情報
| symbol | TTNP |
|---|---|
| 会社名 | Titan Pharmaceuticals Inc (DE) （タイタン・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 Titan Pharmaceuticals Inc. (Titan) is a specialty pharmaceutical company. The Company is engaged in developing therapeutics for the treatment of medical disorders. The Company's segment is engaged in the development of pharmaceutical products. The Company's product development programs utilize its long-term drug delivery platform ProNeura. The Company's drug candidate Probuphine is being developed for the long-term maintenance treatment of opioid dependence. Titan's ProNeura continuous drug delivery system consists of a small solid rod made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The Company focuses on developing two product development programs the first one with a ropinirole implant for the treatment of Parkinson's disease (PD) and the second one with a Triiodothyronine (T3) implant for the treatment of hypothyroidism. タイタン・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。主に、重度な症状に対する治療薬の開発、製造、商品化に従事する。主要薬剤「Probuphine」はオピオイド依存症の治療後の血中濃度を6カ月維持するために使用される注入製剤。また、「Fanapt」は非定型抗精神病薬で、精神分裂症の治療に使用される。本社はカリフォルニア州サンフランシスコ。 Titan Pharmaceuticals, Inc., based in South San Francisco, CA, is a development stage company developing proprietary therapeutics with its ProNeura® long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes. |
| 本社所在地 | 400 Oyster Point Blvd. Suite 505 South San Francisco CA 94080 USA |
| 代表者氏名 | Marc Rubin マーク・ルービン |
| 代表者役職名 | Executive Chairman of the Board 取締役会長 |
| 電話番号 | +1 650-244-4990 |
| 設立年月日 | 33635 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | － |
| url | www.titanpharm.com |
| nasdaq_url | https://www.nasdaq.com/symbol/ttnp |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -10.05200 |
| 終値（lastsale） | 0.21 |
| 時価総額（marketcap） | 4452786.24 |
| 時価総額 | 時価総額（百万ドル） 5.41857 |
| 売上高 | 売上高（百万ドル） 3.83000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 7.34557 |
| 当期純利益 | 当期純利益（百万ドル） -11.32500 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Titan Pharmaceuticals Inc. revenues increased from $117K to $3.7M. Net loss decreased 46% to $3.5M. Revenues reflect License revenue increase from $117K to $3.7M. Lower net loss reflects Research and development - Balancing val decrease of 23% to $3.4M (expense) Stock-based Compensation in S&A decrease of 8% to $515K (expense). |
TTNPのテクニカル分析
TTNPのニュース
Simple Rule To have an eye on this stocks: Aytu BioPharma, Inc. (NASDAQ:AYTU -0.24%), Titan Pharmaceuticals, Inc. (NASDAQ:TTNP -0.69%) 2022/09/14 23:57:35 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Simple Rule To have an eye on this stocks: Aytu BioPharma, Inc. (NASDAQ:AYTU -0.24%), Titan Pharmaceuticals, Inc. (NASDAQ:TTNP -0.69%) appeared first on Stocks Equity .
Titan Pharmaceuticals Inc. (NASDAQ: TTNP) Surged 0.69%, So What Now? 2022/08/06 12:30:00 Stocks Register
Titan Pharmaceuticals Inc. (NASDAQ:TTNP) shares, rose in value on Friday, 08/05/22, with the stock price up by 0.69% to the previous day’s close as strong demand from buyers drove the stock to $1.46. Actively observing the price movement in the last trading, the stock closed the session at $1.45, falling within a range of $1.43 … Titan Pharmaceuticals Inc. (NASDAQ: TTNP) Surged 0.69%, So What Now? Read More »
Hedge Fund and Insider Trading News: George Soros, Jim Simons, Three Arrows Capital, Rocket Companies Inc (RKT), Titan Pharmaceuticals, Inc. (TTNP), and More 2022/07/11 17:29:47 Insider Monkey
Jim Simons and Josh Resnick might not be familiar names to many investors, but both hedge fund managers have beaten the S&P 500 over the past three years.
Tesla, Twitter And 76 Biggest Movers From Friday 2022/07/11 11:30:29 Benzinga
Gainers Seritage Growth Properties (NYSE: SRG ) shares surged 80.3% to settle at $10.96 after the company appointed Adam Metz as Chairman. Preliminary proxy materials also indicated the board recommended shareholders to approve a proposed plan sale. Aditxt, Inc. (NASDAQ: ADTX ) shares climbed 50% to close at $0.24 on Friday after the company''s Adimune therapeutic program completed a toxicology study indicating a favorable safety profile of ADI-100. Waitr Holdings Inc. (NASDAQ: WTRH ) gained 48.5% to settle at $0.35 after the company announced a new partnership with Burq to allow deliveries from several new retail industries. Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) surged 44.4% to close at $8.20. MyMD Pharmaceuticals, Inc. (NASDAQ: MYMD ) jumped 42.1% to close at $4.25 after gaining 9% on Thursday. Kura Sushi USA, Inc. (NASDAQ: KRUS ) climbed 33.6% to close at $72.29 after the company reported better-than-expected Q3 EPS and sales results. The company also issued FY22 sales guidance above analyst estimates.
This Low-Float Stock Jumps Around 148%; Here''s 64 Biggest Movers From Yesterday 2022/07/08 08:15:16 Benzinga
Gainers United Maritime Corporation (NASDAQ: USEA ) climbed 147.6% to close at $7.08 on Thursday on heavy momentum following the company''s recent listing on the Nasdaq Capital Market. Grove Collaborative Holdings, Inc. (NYSE: GROV ) shares climbed 84.3% to close at $7.37 amid news the company''s products will now be available in Kohl''s (NYSE: KSS ), Midwest-based Meijer and also Giant Eagle. American Rebel Holdings, Inc. (NASDAQ: AREB ) jumped 55.7% to close at $1.19. American Rebel Holdings agreed to acquire Utah-based Champion Safe Company and its ancillary companies, in a transaction valued at $9.9 million. Kiromic BioPharma, Inc. (NASDAQ: KRBP ) surged 43.5% to close at $0.5480. Kiromic BioPharma completed the construction of its expanded current good manufacturing practice manufacturing facility in Houston. AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX ) jumped 36.2% to close at $0.3529 after gaining around 4% on Wednesday. Dermata Therapeutics, Inc. (NASDAQ: DRMA ) gained 32.7% to settle at $0.6902.
Boom Or Bust: Where Does Titan Pharmaceuticals Inc. (NASDAQ: TTNP) Stock Go From Here? 2022/06/25 13:30:00 Marketing Sentinel
During the last session, Titan Pharmaceuticals Inc. (NASDAQ:TTNP)’s traded shares were 0.54 million, with the beta value of the company hitting 0.37. At the end of the trading day, the stock’s price was $0.59, reflecting an intraday gain of 0.88% or $0.01. The 52-week high for the TTNP share is $3.10, that puts it down … Boom Or Bust: Where Does Titan Pharmaceuticals Inc. (NASDAQ: TTNP) Stock Go From Here? Read More »
-3.69 Fall Turns Titan Pharmaceuticals Inc. (TTNP) Into A Losing Stock For Investors 2022/04/26 12:30:00 Marketing Sentinel
Titan Pharmaceuticals Inc. (NASDAQ:TTNP) has a beta value of 0.66 and has seen 1.1 million shares traded in the last trading session. The company, currently valued at $9.14M, closed the last trade at $0.74 per share which meant it lost -$0.02 on the day or -3.69% during that session. The TTNP stock price is -318.92% … -3.69 Fall Turns Titan Pharmaceuticals Inc. (TTNP) Into A Losing Stock For Investors Read More »
Opioids Agonist Drugs Market to Signify Healthy Growth by 2027 & COVID-19 impact | Titan pharmaceuticals, Egalet Corporation 2022/03/22 14:54:00 OpenPR
Opioids Agonist Drugs market research report is known as a methodical process of collecting and analyzing the information related to consumers, key pricing structure, competitors, market size, company profiles, target market, growth factors. It makes attentive to major players regarding
Titan Pharmaceuticals Raises $5.5M Via Equity 2022/02/02 17:27:17 Benzinga
Titan Pharmaceuticals Inc (NASDAQ: TTNP ) has announced a private placement of 3.37 million shares and 1.29 million pre-funded warrants. In addition, the Company has agreed to issue to the investor unregistered warrants to purchase up to an aggregate of 4.67 million shares. The combined offering price of each share or pre-funded warrant and Full story available on Benzinga.com
Titan Pharmaceuticals to raise $5.5M in stock and pre-funded warrant offering 2022/02/02 14:08:01 Seeking Alpha
Titan Pharmaceuticals (TTNP) trades 3.9% lower premarket after it entered into a securities purchase agreement with a single institutional investor to purchase 3.37M shares in a
-3.69 Fall Turns Titan Pharmaceuticals Inc. (TTNP) Into A Losing Stock For Investors 2022/04/26 12:30:00 Marketing Sentinel
Titan Pharmaceuticals Inc. (NASDAQ:TTNP) has a beta value of 0.66 and has seen 1.1 million shares traded in the last trading session. The company, currently valued at $9.14M, closed the last trade at $0.74 per share which meant it lost -$0.02 on the day or -3.69% during that session. The TTNP stock price is -318.92% … -3.69 Fall Turns Titan Pharmaceuticals Inc. (TTNP) Into A Losing Stock For Investors Read More »
Opioids Agonist Drugs Market to Signify Healthy Growth by 2027 & COVID-19 impact | Titan pharmaceuticals, Egalet Corporation 2022/03/22 14:54:00 OpenPR
Opioids Agonist Drugs market research report is known as a methodical process of collecting and analyzing the information related to consumers, key pricing structure, competitors, market size, company profiles, target market, growth factors. It makes attentive to major players regarding
Titan Pharmaceuticals Raises $5.5M Via Equity 2022/02/02 17:27:17 Benzinga
Titan Pharmaceuticals Inc (NASDAQ: TTNP ) has announced a private placement of 3.37 million shares and 1.29 million pre-funded warrants. In addition, the Company has agreed to issue to the investor unregistered warrants to purchase up to an aggregate of 4.67 million shares. The combined offering price of each share or pre-funded warrant and Full story available on Benzinga.com
Titan Pharmaceuticals to raise $5.5M in stock and pre-funded warrant offering 2022/02/02 14:08:01 Seeking Alpha
Titan Pharmaceuticals (TTNP) trades 3.9% lower premarket after it entered into a securities purchase agreement with a single institutional investor to purchase 3.37M shares in a
Titan Pharmaceuticals Inc. (NASDAQ:TTNP) Shares Rebounded 9.65% From Their Lows But Can They Continue? 2021/12/24 13:30:00 Marketing Sentinel
In last trading session, Titan Pharmaceuticals Inc. (NASDAQ:TTNP) saw 0.69 million shares changing hands with its beta currently measuring 0.78. Companys recent per share price level of $1.14 trading at -$0.11 or -8.80% at ring of the bell on the day assigns it a market valuation of $11.19M. That closing price of TTNPs stock is Titan Pharmaceuticals Inc. (NASDAQ:TTNP) Shares Rebounded 9.65% From Their Lows But Can They Continue? Read More »